No retraction, correction or concern found when last checked on Oct 30, 2026.
Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes
Andrew B. Crouse, Tiffany Grimes, Peng Li and 3 more
Frontiers in Endocrinology · 2021 · CC BY
doi:10.1101/2020.07.29.20164020
Abstract
Background Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking. Methods We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression. Results The odds ratio of contracting COVID-19 was disproportionately high in Blacks/African-Americans (OR 2.6; 95% CI 2.19–3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95% CI 1.64–2.28; p<0.0001), hypertension (OR 2.46; 95% CI 2.07–2.93; p<0.0001), and diabetes (OR 2.11; 95% CI 1.78–2.48; p<0.0001). Diabetes was also associated with a dramatic increase in mortality (OR 3.62; 95% CI 2.11–6.2; p<0.0001) and emerged as an independent risk factor in this diverse population even after correcting for age, race, sex, obesity, and hypertension. Interestingly, we found that metformin treatment prior to diagnosis of COVID-19 was independently associated with a significant reduction in mortality in subjects with diabetes and COVID-19 (OR 0.33; 95% CI 0.13–0.84; p=0.0210). Conclusion Thus, these results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population.
Cited by papers we hold 6
- Obesity-induced inflammation exacerbates clonal hematopoiesis · 2023No notice
- The Role of Diabetes and Hyperglycemia on COVID-19 Infection Course—A Narrative Review · 2022Not checked
- Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms · 2022No notice
- Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression · 2022No notice
- COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus · 2021Not checked
- Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence · 2021No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.